Welcome to our dedicated page for Nephros news (Ticker: NEPH), a resource for investors and traders seeking the latest updates and insights on Nephros stock.
Nephros Inc. (Nasdaq: NEPH) is a commercial-stage medical device and water technology company dedicated to enhancing water quality in both medical and commercial markets. Founded in 1997 by healthcare professionals affiliated with Columbia University Medical Center, Nephros initially aimed to address the needs of chronic renal failure patients. Today, the company is known for its innovative liquid purification filters that capture contaminants as small as 5 nanometers, significantly reducing exposure to a variety of pathogens, including bacteria, viruses, fungi, parasites, and endotoxins.
The heart of Nephros's technology lies in its proprietary hollow fiber design, which balances three critical elements for optimal filter performance: filtration precision, flow rate, and filter lifespan. These filters are highly efficient, providing up to 12 months of service with minimal disruption in flow rate, making them ideal for both healthcare and commercial applications.
In the medical sector, Nephros offers advanced water filtration products and waterborne pathogen detection tools. These products are essential for maintaining high standards of water safety, particularly in healthcare settings where water quality can directly impact patient outcomes. The company's subsidiary is actively working on a second-generation hemodiafiltration system and other devices aimed at improving therapies for renal disease patients.
In the commercial market, Nephros manufactures water filters designed to enhance the taste and odor of water, while also reducing biofilm, bacteria, and scale buildup in downstream equipment. These products cater to a wide range of industries, including hospitality, food service, and manufacturing, where water quality is a critical factor.
Nephros has recently achieved significant milestones, including:
- Filing its third-quarter financial results on November 8, 2023, with a subsequent conference call to discuss the outcomes.
- Hosting investor relations calls to keep stakeholders informed about company developments.
- Continued commitment to providing cutting-edge water filtration solutions and education to improve water safety.
With a mission to improve the human relationship with water, Nephros remains at the forefront of water technology innovation, offering proactive and emergency solutions to ensure water quality across various sectors. For more information, visit the company's website at Nephros.com.
Nephros, Inc. (NASDAQ: NEPH) has announced a strategic partnership with Donastar Enterprises LLC, appointing it as the exclusive master distributor for its commercial water filters in the food & beverage and hospitality sectors. This partnership, effective immediately, builds on an existing collaboration that has shown promise since early 2022. Nephros aims to improve water quality through innovative filtration solutions, leveraging this alliance to enhance market reach and customer service. Additionally, the timing aligns with the relaunch of Nephros’ product lineup, indicating potential growth in the commercial market.
Nephros, a water technology company specializing in filtration solutions, announced it will release its fourth quarter and fiscal 2022 results on March 8, 2023, after market close. A conference call will follow at 4:30 PM ET. Participants can join via domestic access at 1 (844) 808-7106 or international access at 1 (412) 317-5285. An audio archive will be available post-call on Nephros' investor relations page. The company aims to enhance the human relationship with water by providing innovative filtration products and quality education, serving both healthcare and commercial markets.
Nephros, Inc. (Nasdaq: NEPH) reported preliminary revenue results for Q4 and full year 2022. Q4 net revenue is projected at $2.6 million, a 6% increase quarter-over-quarter but a 6% decline year-over-year. Full-year revenue stands at $10.0 million, down 2% compared to 2021. Despite challenges, the company saw sequential revenue growth and a record of 1,394 Active Customer Sites. Net cash flow improved, with a negative $500,000 in the second half versus $2.9 million in the first half. Nephros ended Q4 with $3.6 million cash.
Nephros, Inc. (Nasdaq: NEPH) reported third-quarter net revenue of $2.4 million, down 7% year-over-year. The company faced a net loss of $1.3 million, an increase from $0.8 million in Q3 2021, influenced by inventory reserve adjustments. Despite a revenue decline, Active Customer Sites rose 18% to a record 1,391. Nephros plans to sell its Pathogen Detection Systems business to cut quarterly expenses by $300,000 and strengthen its financial position. The company maintains a cash balance of $3.9 million, indicating no immediate need for capital raising.
Nephros, a leading water technology company, will announce its third-quarter financial results on November 2, 2022, after market close. A conference call is scheduled for 4:30 PM ET the same day, allowing participants to access the call domestically at 1 (844) 808-7106 or internationally at 1 (412) 317-5285. Interested parties can find an audio archive of the call on Nephros' Investor Relations page.
Nephros, Inc. (Nasdaq: NEPH) announced the sale of its Pathogen Detection Systems (PDS) business to BWSI, aiming to reduce cash burn by approximately $350,000 per quarter. The sale includes a seven-year earn-out provision based on gross profits of PDS products. For Q3 2022, Nephros expects net revenue of $2.5 million and an 18% year-over-year increase in active customer sites, reaching 1,391. The company aims for positive net cash flow by mid-2023, ending Q3 with $3.9 million in cash.
Nephros, Inc. (Nasdaq: NEPH) has successfully shipped 3,000 commercial water filters as part of an ongoing contract with Donastar Enterprises LLC and Tractor Beverage Co. This delivery marks a significant milestone following Nephros's approval as a vendor for a major Quick Service Restaurant (QSR) chain. CEO Andy Astor highlighted the positive momentum and potential for further national contracts, indicating growth in Nephros's commercial water filtration business.
Nephros, a water technology company, announced the appointment of Joe Harris to its Board of Directors on September 8, 2022. Harris, who has over 20 years of healthcare sales management experience, expressed enthusiasm about joining Nephros at a pivotal time for the company's growth and sales momentum. Nephros's President and CEO, Andy Astor, highlighted Harris's financial, sales, and marketing expertise. Nephros specializes in filtration and pathogen detection solutions aimed at both healthcare and commercial markets.
Nephros reported a consolidated net revenue of $2.9 million for Q2 2022, marking a 27% increase year-over-year. The water filtration segment generated $2.8 million, a 30% growth compared to the same quarter last year. Active customer sites reached 1,349, up 21%. Despite this revenue growth, Nephros faced a net loss of $1.1 million, consistent with the previous year. Efforts to optimize costs included price increases and operational adjustments, aiming for positive cash flow by mid-2023.
Nephros, Inc. (Nasdaq: NEPH), a leader in water technology solutions, will announce its second-quarter financial results on August 10, 2022, after market close. A conference call will follow at 4:30 PM ET, accessible by dialing 1 (844) 808-7106 for domestic calls and 1 (412) 317-5285 for international participants. A replay will be available until August 17, 2022. Nephros focuses on innovative filtration and pathogen detection technologies that serve healthcare and commercial markets, aiming to enhance water safety and management.
FAQ
What is the current stock price of Nephros (NEPH)?
What is the market cap of Nephros (NEPH)?
What does Nephros Inc. specialize in?
When was Nephros Inc. founded?
What is the core technology of Nephros filters?
What markets does Nephros serve?
What recent achievements has Nephros announced?
How long do Nephros filters last?
How does Nephros contribute to water safety in medical settings?
What is mid-dilution hemodiafiltration (mid-HDF)?
Who are the key contacts for investor relations at Nephros?
Where can I find more information about Nephros?
